Market Research Report
Global Microarray Market - 2021-2028
|Global Microarray Market - 2021-2028|
Published: February 18, 2022
Content info: 165 Pages
Delivery time: 2 business days
The global microarray market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Microarrays have numerous applications, including basic molecular biology, toxicological response profiling, pharmaceutical target screening, and biomarker identification.
The factors influencing the global microarray market are increased use of microarrays in various applications, and a rise in healthcare R&D is also expected to drive market growth.
The increase in the use of microarrays in a variety of applications is expected to drive market growth in the forecast period
The use of microarrays in oncology is well known. Aside from that, it's used to diagnose various cardiovascular, inflammatory, and infectious diseases and psychiatric disorders. Microarray technology may aid in the discovery of new genes as well as the investigation of their function and expression under various conditions. It entails determining the genetic sequence of all organisms, including humans, mice, and microbes. In Drug and lead discovery, once the target has been identified, microarrays can be used to screen potential compounds and identify the toxicity of the lead compound, which will aid in the selection of the best medication for the patient. Antibodies and microorganisms such as bacteria and viruses are studied to develop more effective antibiotics and vaccines.
And in diagnostics and prognostics, the microarray is widely used to determine the stage of disease, type of tumour, and other important factors for the patient. It is used to diagnose various diseases and infections, most notably cancer. Hence, the increasing application of microarray is expected to drive market growth.
The disadvantages associated with microarray is expected to hamper the market growth
The most significant drawbacks of microarrays are the high cost of a single experiment, many probe designs based on low-specificity sequences, and the lack of control over the pool of analyzed transcripts because most commonly used microarray platforms use only one set of probes designed by the manufacturer. Other limitations of microarrays include their low accuracy, precision, and specificity, as well as the high sensitivity of the experimental setup to changes in hybridization temperature, the purity and degradation rate of genetic material, and the amplification process, all of which, in combination with other factors, may impact gene expression estimates. All these factors are expected to hamper the market growth.
To detect SARS-CoV-2 markers N1 and N2 in nasopharyngeal swabs, researchers used CovidArray, a microarray-based assay. After RNA extraction and reverse transcription, solid-phase hybridization of fluorescently labelled amplicons is used. This method combines the physical-optical properties of the silicon substrate with the surface chemistry used to coat the substrate to create a highly sensitive diagnostic tool. The CovidArray assay is the first to use a DNA microarray to detect viral genes in swabs. Its high sensitivity, combined with RNAGEM's innovative viral RNA extraction, enables the reduction of both the number of false-negative results and the total analysis time to approximately 2 hours. Hence, COVID-19 is expected to have a positive impact on the market.
Based on application, the research segment is expected to dominate the global microarray market
The most well-known application of DNA microarrays is to detect DNA-protein interactions (e.g., transcription factor-binding site and transcription factor), alternatively spliced variants, the epigenetic status of the genome, DNA copy number changes, and sequence polymorphisms. Microarrays' success can be mainly attributed to the versatility and flexibility of array designs and their ability to examine a large number of genes in parallel. Many microarray platforms are available, and custom array designs are feasible and relatively inexpensive. Because microarrays are designed to represent a subset of or the entire genome, it is easy to envision their use in understanding molecular and genome evolution.
Furthermore, advances in mapping and quantitative trait analysis in microarrays can greatly benefit ecological genetic studies. DNA microarrays are a powerful, mature, versatile, and simple-to-use genomic tool for biomedical and clinical research. This approach is being used for new applications by the research community. The main benefit is that genomic-wide information is available at a reasonable cost. On the other hand, biological interpretation necessitates the integration of multiple sources of data.
North America region is expected to hold the largest market share in the global microarray market
The increase in the incidence of cancer patients in the U.S. and the rise in R&D in this region are expected to drive market growth. Microarray technology allows researchers to simultaneously monitor the RNA expression levels of thousands of genes in primary tumors and cell lines. In theory, the findings of such studies could revolutionize cancer diagnosis.
Microarray technology allows researchers to simultaneously monitor the RNA expression levels of thousands of genes in primary tumors and cell lines. DNA micro-array-based tumor gene expression profiles have recently been developed and are being used in tumor diagnosis and classification. In 2018, 1,708,921 new cancer cases were reported in the United States, and 599,265 people died from cancer. There were 436 new cancer cases reported for every 100,000 people, and 149 people died from cancer. Hence, the increasing incidence of cancer is expected to rise the demand for microarray and drive market growth.
The global microarray market is moderately competitive with company mergers, collaborations, and product launches. Some of the key players in the market are Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., PerkinElmer Inc., Merck KGaA, Cytiva, Molecular Devices, LLC, Arrayit Corporation, and Microarrays, Inc.
Agilent Technologies Inc.
Overview: Agilent Technologies, Inc. is an American analytical instrument development and manufacturing company that serves worldwide products and services. The company's global headquarters are in Santa Clara, California. Agilent was founded as a spin-off from Hewlett-Packard in 1999.
Product Portfolio: The platform for Gene Expression Microarray is for workflows and research. From sample to results, it offers a complete platform that includes Gene Expression & Exon Microarrays, Buffers, Kits & Reagents, Scanners & Equipment, Software, and Supplies.
Key Developments: On 29th April 2019, Agilent Technologies Inc. and SomaLogic, Inc. signed a multi-year supply agreement in which Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step of SomaLogic's novel SOMAscan assay, a protein measurement platform with applications in basic and clinical research, diagnostics, and pharmaceutical discovery and development.
The global microarray market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.
Global Microarray Market- By Product
Global Microarray Market- By Type
Global Microarray Market- By Application
Global Microarray Market- By Region
LIST NOT EXHAUSTIVE